Psychedelic Weekly Headlines | September 16th

September 16, 2022
Headlines

Helping investors discover, understand, and stay up-to-date on market news and investment opportunities within the Psychedelic industry.


Markets

Performance of psychedelic public companies this past week.


Company News

Algernon Pharmaceuticals ($AGN | $AGNPF) received approval to conduct a Phase I clinical study for their DMT-based psychedelic compound, AP-188, for the treatment of stroke. Algernon's preclinical study showed that DMT increased growth of neurons by 40%. Press Release          

Awakn Life Sciences ($AWKN | $AWKNF) signed a drug development agreement with Catalent, a global leader in enabling biopharma, cell, gene, and consumer health, to investigate a proprietary formulation and optimized delivery route for MDMA using Catalent's proprietary Zydis orally disintegrating tablet technology. Press Release    

Nova Mentis Life Science ($NOVA | $NMLSF) completed production of psilocybin microdose capsules in collaboration with the Toronto Institute of Pharmaceutical Technology. Nova Mentis is currently preparing to submit a clinical trial application for a Phase IIa study evaluating psilocybin microdose therapy for fragile X syndrome. Press Release          

Sunstone Therapies (Private) an organization dedicated to the treatment of the psychological effects of cancer has partnered with MAPS to conduct a clinical trial focused on the safety and tolerability of MDMA-assisted therapy for patients with treatment-resistant PTSD. Press Release          

Revive Therapeutics ($RVV | $RVVTF) provided an update on their Phase I/II clinical study of oral psilocybin as a potential treatment of methamphetamine use disorder and the development of their proprietary oral psilocybin thin film strip product. Revive's Phase I/II clinical study received both FDA and Institutional Review Board approval. Press Release          

Seelos Therapeutics ($SEEL) announced the participation of Acadia Healthcare ($ACHC) in their Phase II clinical trial of SLS-002, an intranasal racemic ketamine, for Acute Suicidal Ideation and Behavior in patients with MDD. Acadia Healthcare operates a network of nearly 240 behavioral health facilities in the United States. Press Release          

Braxia Scientific ($BRAX | $BRAXF) successfully launched KetaMD in Florida and completed initial at-home ketamine treatments. KetaMD is an innovative telemedicine platform, that provides access to safe, affordable, at-home ketamine treatments for people suffering from mental health disorders such as depression, bipolar disorder, anxiety and PTSD. Press Release          


Media

The Washington Post: Ketamine For Depression: What It Feels Like And Who It Can Help          

Fox: Former Navy SEAL: Psychedelics 'Saved My Life'          

Wall Street Journal: Investors Bet Ketamine Treatment Will Revolutionize Mental-Health Care          

NPR: Thousands Of Moms Are Microdosing With Psychedelics To Ease The Stress Of Parenting          


Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.

Always do your own research and make your own investment decisions. This is not a solicitation to purchase or sell securities. Psychedelic Finance is not a registered investment advisor and does not purport to provide investment advice, whether implied or otherwise. Psychedelic Finance does not independently verify the accuracy or the truth of the statements or representations made by issuers. This message is meant for information and educational purposes only and Psychedelic Finance does not intend for this information to be used to inform an investment decision.